Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib
The Oncologist · 04.07.2025 · 30 (7)
DOI: 10.1093/oncolo/oyaf146 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Oncologist, online erschienen am 28.07.2025. Verfasst von Federico Villanacci und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Azienda USL Toscana Nord-ovest, Livorno Hospital, Livorno, Italy. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Brain Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment options and poor prognosis. Epidermal growth factor receptor (EGFR) alterations, including amplifications, mutations, and fusions, are prevalent in GBM and represent potential therapeutic targets. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), has demonstrated efficacy in EGFR-mutated non-small cell lung cancer and central nervous system metastases. However, its efficacy in GBM remains uncertain. We present 2 cases of recurrent GBM harboring distinct EGFR alterations treated with osimertinib. Both patients, despite showing EGFR amplification or activating mutations (G719D), experienced rapid disease progression and clinical deterioration during treatment. These findings highlight the resistance of GBM to osimertinib, possibly due to tumor heterogeneity, subclonal variation, or intrinsic mechanisms linked to EGFR amplification and redundant oncogenic pathways. Our observations align with prior trials of EGFR-TKIs in GBM, which have shown limited benefit. These cases underscore the complexity of targeting EGFR in GBM and the need for advanced therapeutic approaches, including next-generation EGFR inhibitors and antibody-drug conjugates, to overcome resistance. Further studies are crucial to optimize EGFR-targeted therapies in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Azienda USL Toscana Nord-ovest, Livorno Hospital, Livorno, Italy.
- Inserm U1127, CNRS UMR 7225, Institut du Cerveau, ICM, Charles Foix, Service de Neuro-oncologie, Sorbonne Université, AP-HP, Hôpitaux Universitaires la Pitié Salpêtrière, Paris, France.
- Department of Neurosurgery, Hôpitaux Universitaires la Pitié Salpêtrière, Paris, France.
- Department of Anatomic Pathology, Azienda USL Toscana Nord-ovest, Livorno Hospital, Livorno, Italy.
- ASL Toscana Nord Ovest, Pathology Unit, Centro Polispecialistico "Achille Sicari," Carrara, Italy.
- Department of Radiation Oncology, AP-HP, Hôpitaux Universitaires la Pitié Salpêtrière, Paris, France.
ORCID-Profile: Mehdi Touat, Anna Luisa Di Stefano
Zitieren
APA
Villanacci, F., Prost, D., Pieri, F., Boetto, J., Zucchi, V., Giusti, A., Jacob, J., Nichelli, L., Cupini, S., Allegrini, G., Della Porta, M., Santonocito, O. S., Touat, M., & Di Stefano, A. L. (2025). Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib. The Oncologist, 30(7). https://doi.org/10.1093/oncolo/oyaf146
Vancouver
Villanacci F, Prost D, Pieri F, Boetto J, Zucchi V, Giusti A, et al. Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib. The Oncologist. 2025;30(7). doi:10.1093/oncolo/oyaf146
BibTeX
@article{Villanacci2025,
author = {Villanacci, Federico and Prost, Diego and Pieri, Francesco and Boetto, Julien and Zucchi, Vanna and Giusti, Andrea and Jacob, Julian and Nichelli, Lucia and Cupini, Samanta and Allegrini, Giacomo and Della Porta, Mauro and Santonocito, Orazio Santo and Touat, Mehdi and Di Stefano, Anna Luisa},
title = {Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {7},
doi = {10.1093/oncolo/oyaf146}
}
EUVIMED